Abstract 219P
Background
Radical radiotherapy is the mainstay of bladder preservation treatment for muscle-invasive bladder cancer (MIBC) patients. The concurrent use of radiosensitisers improves patient outcome (Caffo et al., 2016, Hoskin et al., 2010). However, different factors may preclude patients from receiving radiosensitisers. This retrospective study evaluates the survival and toxicity outcomes of bladder preservation treatment in a tertiary cancer centre.
Methods
Patients treated with radical radiotherapy from 2010 to 2017 were divided into two groups depending on whether they received radiosensitisers in addition to radiotherapy. The primary outcome was overall survival (OS) and the secondary outcome was rate of late toxicities. Kaplan-Meier analyses were used to analyse OS. Late genitourinary (GU) and gastrointestinal (GI) toxicities were defined as treatment-related toxicities at 1-year post-treatment, assessed on the LENT/SOMA scale.
Results
A total of 428 patients were included in the survival analysis. 303 patients had combination treatment while 125 patients had radiotherapy alone. Patients in the combination group were younger (median age 72 vs 81, p < 0.001), have better performance status (PS 0-2 298 (95%) vs 115 (92%), p < 0.001), and fewer comorbidities compared to patients in radiotherapy alone group. The median follow-up for this study was 56 months. The median OS was 76 months (95% CI: 66-NA) in radiosensitiser group compared to 13 months in radiotherapy only group (95% CI: 13-21) (p < 0.001, HR = 3.09 (95% CI: 2.32-4.12)). As shown in the table, the incidence of late toxicity was low in both groups and formal analysis could not be carried out.
Table: 219P Rates of late toxicities following radical radiotherapy
Combination (N = 303) | Radiotherapy (N = 125) | |
---|---|---|
GU Toxicity | ||
Any grade | 119 (39.3%) | 2 (1.6%) |
Grade 3-4 | 4 (1.3%) | 1 (0.8%) |
GI Toxicity | ||
Any grade | 133 (43.9%) | 2 (1.6%) |
Grade 3-4 | 4 (1.3%) | 0 (0%) |
Conclusions
The survival outcome with radiosensitisation in this real-world retrospective study is in keeping with published data. Bladder preservation is effective with minimal long-term toxicities. Patients with localised MIBC should be offered the option of bladder preservation treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Radiotherapy-Related Research Group, The Christie Hospital NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract